Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! By
Docking and Molecular Dynamics Simulations of Flavonoids As Inhibitors of Infectious Agents: Rutin As a Coronavirus Protease Inhibitor Publisher



Salarizadeh N1, 3 ; Aallaei MR2 ; Zarei A3 ; Malekshah RE4 ; Molaakbari E2 ; Farajnezhadi A5
Authors

Source: ChemistrySelect Published:2022


Abstract

3CL protease as the main protease (Mpro) of coronavirus is investigated as a potential target in medicine. Flavonoid compounds with polyphenolic structures exhibited anti-viral, anti-bacterial, immunomodulatory and anti-inflammatory effects against infectious agents. In this study, the inhibitory effect of flavonoid-based compounds was evaluated against coronavirus Mpro using molecular docking and dynamic simulations. Molegro Virtual Docker 6.0 (MVD) software was used to ensure the accuracy of the docking analysis. Eventually, four compounds including two herbal-based (Rutin and Quercetin) and two chemical-based (2-Iodoadenosine-5’-O-[(phosphonomethyl)phosphonic Acid] and Camostat) are selected based on the interaction energies and docking scores of the investigated structures. The values of MolDock Score for Rutin was −174.355 docked to Mpro enzyme. The molecular dynamics was performed by using GROMACS in 100 ns to refine the docking simulation results and evaluated the binding stability of Rutin. Potential energy of Rutin/Mpro complex stabilization was measured approximately −1.11×106 kcal/mol for 100 ns. As a result, Rutin is suggested as a potent inhibitor for Mpro and can be used as an effective drug in the treatment and prevention of covid. © 2022 Wiley-VCH GmbH.
Other Related Docs
4. Antiviral Activity of Medicinal Plants Against Human Coronavirus: A Systematic Scoping Review of and Experimentations, Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan (2022)
12. Tankyrase Inhibitor for Cardiac Tissue Regeneration: An In-Silico Approach, Iranian Journal of Pharmaceutical Research (2021)